7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines

NEXT STORY
Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021
PREV STORY
Aceragen Announces Acquisition of Arrevus, Expands Late-Stage Rare Disease Pipeline
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia

Chicago, IL, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty ...

author_avatar
NASDAQ Market News

Aileron Therapeutics Announces Expansion of Scientific Advisory Board

CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader ...

author_avatar
NASDAQ Market News

FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Capital Notes into shares

FIT Biotech Oy Company release December 8, 2017 at 04:00 PM EET Conversion of ...

author_avatar
NASDAQ Market News